Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma

Kyle LaHucik

Senior Reporter

Bing Yao’s ArriVent BioPharma has inked another licensing deal with a Chinese biopharma. The late-stage oncology biotech is picking up a new antibody-drug conjugate from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

On­col­o­gy biotech Ar­riVent does an­oth­er Chi­na ADC deal, this time with Lepu Bio­phar­ma

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma